-
公开(公告)号：US20220289819A1
公开(公告)日：2022-09-15
申请号：US17770500
申请日：2019-11-07
Inventor： Mi-Young OH , Jae-Chul LEE , Hye Young PARK , Hye In YUM , Dong-Sik KIM
IPC: C07K14/705 , C07K16/28 , A61P35/00
Abstract: A steric epitope of CEACAM1 is disclosed. An anti-CEACAM1 antibody or a fragment thereof, which specifically binds to CEACAM1 is disclosed. A steric epitope of CEACAM1 includes all amino acids in critical positions for specific binding to an anti-CEACAM1 antibody and maintains an appropriate three-dimensional structure, and thus can high affinity for an anti-CEACAM1 antibody. In addition, an antibody, or a fragment thereof, that specifically binds to a steric epitope can effectively suppress CEACAM1-CEACAM1 interaction and CEACAM1-CEACAM6 interaction.
-
Patent Agency Ranking
公开(公告)号：US20230417748A1
公开(公告)日：2023-12-28
申请号：US18035235
申请日：2021-11-05
Inventor： Dong-Sik KIM , Sua LEE , Shin A JANG , Jihoon KANG , KI Joon CHO , Soo Bin PARK , Young Woo HAN , Hyemi NAM , Mi Young OH , Jee Boong LEE , Jihye RYU , Mun Kyung KIM , Jeewon LEE
IPC: G01N33/569 , C07K16/10 , A61K47/68
CPC classification number: G01N33/56983 , C07K16/1003 , A61K47/6841 , G01N2333/165 , G01N2469/10 , C07K2317/56 , C07K2317/33 , C07K2317/24 , C07K2317/52 , C07K2317/732 , C07K2317/73
Abstract: Provided are a coronavirus spike (S) protein-specific antibody and use thereof.
-
公开(公告)号：US20180346588A1
公开(公告)日：2018-12-06
申请号：US15762885
申请日：2016-09-23
Inventor： Dong-Sik KIM , Eun Jung SONG , Mijung LEE , Eun-Hee LEE , Miyoung OH , Jae Chan PARK , Kisu KIM , Sujeong KIM , Hyung-Kwon LIM , Kyuhyun LEE , Jongwha WON , Soongyu CHOI , Young Seoub PARK
IPC: C07K16/30
CPC classification number: C07K16/30 , C07K16/18 , C07K2317/21 , C07K2317/565 , C07K2317/92
Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.
-
公开(公告)号：US20220275360A1
公开(公告)日：2022-09-01
申请号：US17058124
申请日：2019-05-31
Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventor： Dong-Sik KIM , Mi Jung LEE , Mi Young OH , Hye-Ji CHOI , Gil-Jung KIM , Shin A JANG , Ae Rin YOON
Abstract: The present invention relates to a novel antibody library and an antibody-screening method using same. Having a human sequence-derived specific VH or VL scaffold, the antibody library according to the present invention exhibits high thermodynamic stability and enjoys the advantages of allowing high soluble expression as well as reversible folding. In addition, the antibody according to the present invention includes a variety of rationally controlled CDRs so as to exhibit high specificity and high affinity to all antigens and thus can be advantageously used for selecting an adequate candidate antibody against a target antigen.
-
公开(公告)号：US20180346592A1
公开(公告)日：2018-12-06
申请号：US15771527
申请日：2016-10-27
Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventor： Jae Chan PARK , Kisu KIM , Mijung LEE , Eun-Hee LEE , Dong-Sik KIM , Eun Jung SONG , Sujeong KIM , Hyung-Kwon LIM , Kyuhyun LEE , Jongwha WON , Soongyu CHOI , Young Seoub PARK
CPC classification number: C07K16/303 , A61K47/6859 , C07K2317/31 , C07K2317/622
Abstract: The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.
-
公开(公告)号：US20180030151A1
公开(公告)日：2018-02-01
申请号：US15553292
申请日：2015-12-29
Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventor： Dong-Sik KIM , Mi Jung LEE , Jae Chan PARK , Sumin LEE , Heechun KWAK , SungHo HWANG , Hyung-Kwon LIM , Kisu KIM , Young Seoub PARK , Junhong JEONG , Ki Joon CHO
IPC: C07K16/38
CPC classification number: C07K16/38 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/72 , C07K2317/92
Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
-
-
-
-
-
Search Results
6
records
(took 0.023 seconds)
